Payment overview · 2025
General Payments
$47,712.14
147 reported records · 24 companies
Healthcare provider profile · identity verified
Jeffrey S Deitch, DO
Allopathic & Osteopathic Physicians|Family Medicine · STERLING HEIGHTS, MI · NPI 1386634749
Verified facts
What the public records show
CMS Open Payments records show Jeffrey S Deitch, DO received $47,712.14 in general payments during 2025 across 147 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 62.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $29,577.11 | 62.0% | 41 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16,525.15 | 34.6% | 32 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $422.64 | 0.9% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $269.14 | 0.6% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $230.24 | 0.5% | 12 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $90.24 | 0.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.15 | 0.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.61 | 0.1% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $51.36 | 0.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $48.25 | 0.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.62 | 0.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $43.12 | 0.1% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$36.84 | 0.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.70 | 0.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $31.44 | 0.1% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $28.74 | 0.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.73 | 0.1% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.66 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.21 | 0.0% | 1 | 2025 |
| Krystal Biotech Inc | Unresolved — no canonical attribution shown | $18.13 | 0.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.41 | 0.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.31 | 0.0% | 1 | 2025 |
| Validus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.83 | 0.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $13.51 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,725.00 | 17 |
| Travel and Lodging | $8,876.08 | 34 |
| Consulting Fee | $3,906.75 | 2 |
| Food and Beverage | $3,092.82 | 93 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $29,465.62 | 40 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $16,551.88 | 33 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $377.71 | 16 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $216.33 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $180.49 | 9 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $180.49 | 9 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $180.49 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $109.45 | 8 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $90.24 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $70.15 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $52.81 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.81 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $51.36 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.75 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.75 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48.25 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.62 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.93 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $43.12 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $36.84 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $31.44 | 2 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| VYJUVEK Normalized: vyjuvek |
Drug | Krystal Biotech Inc | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| RALDESY Normalized: raldesy |
Drug | Validus Pharmaceuticals LLC | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 249 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
249 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 531 | 186 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 109 |
| Losartan Potassium | Losartan Potassium | 307 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 286 | 98 |
| Eliquis | Apixaban | 249 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 72 |
| Furosemide | Furosemide | 205 | 78 |
| Gabapentin | Gabapentin | 190 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 54 |
| Lisinopril | Lisinopril | 173 | 58 |
| Omeprazole | Omeprazole | 173 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 52 |
| Metformin Hcl | Metformin Hcl | 143 | 55 |
| Alprazolam | Alprazolam | 142 | 30 |
| Trazodone Hcl | Trazodone Hcl | 129 | 46 |
| Simvastatin | Simvastatin | 127 | 38 |
| Ezetimibe | Ezetimibe | 123 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 104 | 21 |
| Allopurinol | Allopurinol | 101 | 32 |
| Famotidine | Famotidine | 100 | 26 |
| Carvedilol | Carvedilol | 99 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 30 |
| Potassium Chloride | Potassium Chloride | 92 | 33 |
| Methylprednisolone | Methylprednisolone | 90 | 74 |
| Ozempic | Semaglutide | 89 | 20 |
| Sertraline Hcl | Sertraline Hcl | 84 | 33 |
| Levetiracetam | Levetiracetam | 83 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 28 |
| Lorazepam | Lorazepam | 74 | 17 |
| Finasteride | Finasteride | 71 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 22 |
| Tramadol Hcl | Tramadol Hcl | 69 | 39 |
| Meloxicam | Meloxicam | 67 | 35 |
| Azithromycin | Azithromycin | 64 | 59 |
| Latanoprost | Latanoprost | 64 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 19 |
| Donepezil Hcl | Donepezil Hcl | 60 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 41 |
| Montelukast Sodium | Montelukast Sodium | 59 | 22 |
| Jardiance | Empagliflozin | 58 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 38 |
| Mounjaro | Tirzepatide | 53 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 19 |
| Januvia | Sitagliptin Phosphate | 52 | 14 |
| Terazosin Hcl | Terazosin Hcl | 50 | 13 |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 13 |
| Bupropion Xl | Bupropion Hcl | 40 | 11 |
| Prednisone | Prednisone | 40 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 14 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Glimepiride | Glimepiride | 37 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 12 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 30 |
| Mirtazapine | Mirtazapine | 34 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 23 |
| Bumetanide | Bumetanide | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 21 |
| Digoxin | Digoxin | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 15 |
| Atenolol | Atenolol | 25 | 12 |
| Nifedipine Er | Nifedipine | 25 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | 14 |
| Xarelto | Rivaroxaban | 25 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 15 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Ursodiol | Ursodiol | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 12 |
| Diazepam | Diazepam | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 15 | suppressed |
| Sympazan | Clobazam | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $47,712.14 · 147 records | Teva Pharmaceuticals USA, Inc. | ABRYSVO, AUSTEDO XR, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EDARBI, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, EVENITY, GEMTESA, INCEPTIV, KISUNLA, Kerendia, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, RALDESY, REPATHA, REXULTI, Rybelsus, SHINGRIX, VRAYLAR, VYJUVEK, Veozah, WATCHMAN FLX, Wegovy, XIFAXAN, YUPELRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error